We value your privacy

We use necessary cookies to make this site work, and Google Analytics to measure visits (it sets cookies and is not affected by the choices below). With your consent, we also use our own analytics cookies to understand how the site is used and improve it. Privacy policy

XOOBAY 数贝环球
金盒集团
金盒集团

金盒集团

Premier Elite

5
Products
0
Followers
2013
Established

The NYSE-listed SPAC shell company GFOR announced today that it has entered into a De-SPAC merger agreement with a biotechnology enterprise.

The NYSE-listed SPAC shell company GFOR announced today that it has entered into a De-SPAC merger agreement with a biotechnology enterprise.

On April 14, 2023, NKGen Biotech, Inc., a clinical-stage biotech company focused on the development and commercialization of innovative autologous, allogeneic, and CAR-NK natural killer ("NK") cell therapies, and Graf Acquisition Corp. IV (NYSE: GFOR, GFOR.U, GFOR WS), a New York Stock Exchange-listed special purpose acquisition company co-founded by serial SPAC founders James Graf, Sabrina McKee, and Tony Kuznik, today announced that the two parties have entered into a definitive agreement for a business combination.

Following the completion of the business combination, Graf will be renamed "NKGen Biotech, Inc." and is expected to list on the New York Stock Exchange, NYSE American, or Nasdaq under the stock ticker symbol "NKGN".

NKGen Biotech is a biotechnology company dedicated to the development and commercialization of innovative immune cell therapies for the treatment of cancer, inflammatory diseases, and neurodegenerative diseases. Founded in 2017, the company is headquartered in Santa Ana, California, USA. NKGen's primary backer is South Korean public company NKMax Co., Ltd., which holds the exclusive license to NKGen's intellectual property in markets outside of Asia.

NKGen leverages cell expansion and activation technologies, as well as cell therapy manufacturing expertise, to scale natural killer cells at commercial scale while significantly enhancing cytotoxicity. NKGen's current lead product candidate is SNK01, which is undergoing a Phase 1 clinical trial for advanced Alzheimer's disease in Mexico, and two Phase 1/2 clinical trials for advanced refractory solid tumors in the United States.

NKGen owns a 25,000 square-foot, cGMP-compliant commercial manufacturing facility in Santa Ana, California. The company is led by Chief Executive Officer Paul Y. Song, M.D., who was the first employee to join NKGen in 2017.

Paul Y. Song, M.D., Chief Executive Officer of NKGen, stated, "The Graf team fully understands and appreciates our innovative NK cell therapy platform technology and our overall mission to help patients with unmet clinical needs, particularly those suffering from neurodegenerative diseases. We believe this business combination is a critical step in our overall growth strategy. We believe accessing the public markets will help us fund clinical development for advanced neurodegenerative diseases and support our off-the-shelf allogeneic programs in oncology." Dr. Song commented, "We look forward to demonstrating our technology and the many key roles NK cells play in human health, and we aim to show that our autologous (SNK01), allogeneic (SNK02), and CAR-NK product portfolio can be used not only for cancer treatment, but also for neurodegenerative and autoimmune diseases."

James Graf, Chief Executive Officer of Graf, stated, "We are excited to partner with Sangwoo, Paul, and the entire NKGen team to help realize their long-term potential. Graf reviewed numerous potential biotechnology companies, and NKGen truly impressed our team after reviewing its scientific achievements, differentiated production, and cryopreservation technologies. But what really resonated with us was NKGen's commitment to developing therapies for the unmet needs in the neurodegenerative disease space."

NKGen Founder and Executive Chairman, and NKMax Chairman and Chief Executive Officer Sangwoo Park added, “We are excited to take this next step to potentially bring innovative therapies to patients who currently have limited options. The guiding force behind our company has always been focused on improving patients’ lives. The passion and commitment the NKGen team has demonstrated in fulfilling this mission are the pillars of our company.” Mr. Park also stated, “The business combination with Graf is an important step in our long-term strategy to become a leader in NK cell therapies. We expect the combined business may provide much-needed funding for our clinical trials in neurodegenerative diseases and oncology.”

The transaction values NKGen Biotech, Inc. at $145 million on a pro forma basis, and the business combination has been approved by the boards of directors of NKGen and Graf, as well as NKMax, and is expected to close in the third quarter of 2023.

Cooley LLP serves as legal counsel to NKGen and NKMax. White & Case LLP serves as legal counsel to Graf.

Originally published on 金盒企业管理集团